Showing posts with label stem cells multiple sclerosis. Show all posts
Showing posts with label stem cells multiple sclerosis. Show all posts

Wednesday, August 8, 2012

Jorge Paz MD – Adult Stem Cell Therapy for Arthritis, Sports Injury, and Autoimmune Diseases (Part 2 of 3) || Video



Stem Cell Institute Spring Seminar 2012
Gilbert, AZ

Stem cell Treatment protocol for autoimmune diseases such as rheumatoid arthritis. Why stem cells must be administered systemically for autoimmune diseases. Dr. Paz elaborates on the disadvantages of same-day fat-derived stem cell treatments. He presents the scientific rationale for treating rheumatoid arthritis (RA) with fat-derived stem cells along with a published case report including patient video. Presentation of similarities between MS and RA and how MS is treated with a combination of human umbilical cord-derived stem cells and adiopose stem cells. Dr. Paz discusses why MS treatment includes umbilical cord-derived stem cells.

Jorge Paz, MD is the Medical Director at the Stem Cell Institute in Panama City, Panama

More information at www.cellmedicine.com

Monday, May 21, 2012

Multiple Sclerosis Treatment Success Using Mesenchymal Stem Cell-Secreted Factors in Animal Model

Stem cell researchers at Case Western Reserve have reported in Nature Magazine that the functional deficits caused by multiple sclerosis can be reduced by administering mesenchymal stem cell secreted factors.

While previous studies have shown promising results using mesenchymal stem cells, this is the first time that such results have been reported without using the stem cells themselves.

The Stem Cell Institute's Founder, Neil Riordan PhD, originally cited the potential therapeutic role of mesenchymal stem cell trophic factors in the 2010 Cellular Immunology publication: Mesenchymal Stem Cells as Anti-inflammatories: Implications for Treatment of Duchenne Muscular Dystrophy

In addition to reducing functional deficits, the development of new myelinating oligodendrocytes and neurons, release of inflammatory cytokines, and suppression of immune cells influx were also observed in the Case Western study.

Details can be found here:

http://www.nature.com/neuro/journal/vaop/ncurrent/full/nn.3109.html

Hepatocyte growth factor mediates mesenchymal stem cell–induced recovery in multiple sclerosis models

Lianhua Bai, Donald P Lennon, Arnold I Caplan, Anne DeChant, Jordan Hecker, Janet Kranso, Anita Zaremba Robert H Miller


Nature Neuroscience (2012) doi:10.1038/nn.3109
Received 18 January 2012 Accepted 17 April 2012 Published online 20 May 2012

Abstract

Mesenchymal stem cells (MSCs) have emerged as a potential therapy for a range of neural insults. In animal models of multiple sclerosis, an autoimmune disease that targets oligodendrocytes and myelin, treatment with human MSCs results in functional improvement that reflects both modulation of the immune response and myelin repair. Here we demonstrate that conditioned medium from human MSCs (MSC-CM) reduces functional deficits in mouse MOG35–55-induced experimental autoimmune encephalomyelitis (EAE) and promotes the development of oligodendrocytes and neurons. Functional assays identified hepatocyte growth factor (HGF) and its primary receptor cMet as critical in MSC-stimulated recovery in EAE, neural cell development and remyelination. Active MSC-CM contained HGF, and exogenously supplied HGF promoted recovery in EAE, whereas cMet and antibodies to HGF blocked the functional recovery mediated by HGF and MSC-CM. Systemic treatment with HGF markedly accelerated remyelination in lysolecithin-induced rat dorsal spinal cord lesions and in slice cultures. Together these data strongly implicate HGF in mediating MSC-stimulated functional recovery in animal models of multiple sclerosis.

Friday, May 11, 2012

Latest Stem Cell Therapy Protocol for Multiple Sclerosis

For the latest information on combination stem cell treatment protocol for MS using the patient's own adipose-derived mesenchymal stem cells and donated human umbilical cord tissue-derived mesenchymal stem cells, please visit:

http://www.cellmedicine.com/treatment/multiple-sclerosis/

Friday, April 27, 2012

Great Day in Ft. Worth for Stem Cell Team

Saturday, March 31 was the annual MS Walk in Ft Worth. This year, thanks to the Stem Cell Institute and some of the area stem cell patients, several of us MS sufferers and stem cell patients met for the Walk. Here’s a picture of several of us who have been to Panama, or Costa Rica, for treatments – (from L – R) Richard, Carolyn, Shelley, Carla, Judi, Holly, and me. We wanted to give the Stem Cell Institute a presence in that sea of MS victims and caregivers. I wish all of them knew that many of us in those blue t-shirts were there walking, actually completing the whole mile, even though we were once unable to do such. I wanted to grab that microphone that the organizers were using and tell all of them “There is HOPE – it doesn’t have to be what you hear from your doctors so often. It can be more than ‘Let’s keep taking this medication so you might get worse at a slower rate’ ” I personally never heard about the possibility of actually improving when I went to good doctors here in the US – but I chose to try the Stem Cell treatment in Panama, and I walked that mile on Saturday! A year ago, six months ago, I couldn’t have done that – but after my third trip to Panama in September, my walking, my balance, and my stamina all improved dramatically. And many of those in our group on Saturday have a similar story; some results more dramatic than others, but most all of us have seen and felt the changes that give us that Hope that all of those sufferers at the Walk are looking for. THANKS STEM CELL INSTITUTE! Sam Harrell Sam in Panama

Wednesday, April 18, 2012

Quality time: Former Ennis coach Sam Harrell is counting his blessings despite having multiple sclerosis

ENNIS, TX -- Sam Harrell's three state football championships are celebrated in his home office. He has pictures, trophies and balls, and even more memories. For 32 years, Harrell worked in a profession where success is measured by a scoreboard in front of thousands. These days, life's little victories -- unaccompanied by cheers or Gatorade showers -- are just as satisfying. Harrell can jump up and down in his living room. He can walk across a parking lot without a cane or a walker. He can spend hours at Kolache Depot Bakery without getting fatigued. Harrell hasn't beaten multiple sclerosis, but he is successfully living with it. "It puts everything in perspective," Harrell said. "Now, I'd rather play catch with my grandson in the back yard than win a state championship. When that gets taken away from you, you realize how precious it is."

Harrell was 153-51 in 16 seasons at Ennis, winning Class 4A state titles in 2000, '01 and '04. He coached all three of his sons -- Graham, now a backup quarterback with the Green Bay Packers; Zac, the offensive coordinator at Van High School; and Clark, who finished his college career at Abilene Christian in 2010 and now works as a financial planner.

It was in 2005, while he was on the tennis court, that Harrell's vision in one eye became blurry. An eye specialist sent him to a neurologist, who, after running tests, gave Harrell the best possible diagnosis: He had MS. "I didn't know whether I was supposed to cheer or cry," Harrell said. "I got the best of the three things it could be, but the bad news is: I have MS." Multiple sclerosis is a chronic, unpredictable disease that affects the central nervous system. The immune system eats away the myelin sheath surrounding the nerves. Symptoms vary from person to person. Mild symptoms include numbness in the limbs, weakness, fatigue and blurred vision. Severe symptoms include paralysis and loss of vision. There is no known cure for MS.

Harrell chose to keep the news a secret from everyone except his wife, Kathy. He didn't reveal the diagnosis for four years, though, as his condition worsened, those close to Harrell knew something was wrong. "We'd go to practice, and he had to take a golf cart," Graham Harrell said in a phone interview after a recent Packers practice. "Sometimes he was off balance a little bit, or shaky walking. So there were times we knew something wasn't quite right, but we didn't know exactly what was going on until he finally told us. "It was hard to watch, obviously, especially with him wanting to coach, and yet not being able to do it like he used to. But recently, he's seen great improvement, and that's huge encouragement not only to him, but to us, and hopefully he'll continue to get better."

Sam Harrell knew his MS wouldn't kill him, but he thought not coaching might. Sam's father, Jake, established the family business at Seminole, where he spent 20 seasons, including 10 as the head coach. But Sam Harrell's health forced him to quit coaching before the 2010 season. "That's all I'd done my whole life," Harrell said, "so I was sick about it. I just didn't know what I was going to do. "I do wish I could still do it, but I haven't died from not coaching."

Harrell, in fact, is alive and well. He credits three trips to Panama for his improved health. After he retired from coaching, Harrell began researching regenerative medicine. Stem cell treatment is not approved in the United States, but Dr. Neil Riordan, who lives in Trophy Club, is the founder of the Stem Cell Institute in Panama. Riordan is one of the leading stem cell scientists in the world. Harrell talked to several of Riordan's patients, including Richard Humphries, a golf coach out of Diamond Oaks Country Club in Fort Worth. Humphries was diagnosed with MS in 2005.

He began stem cell treatments in 2008. Stem cell treatments introduce new cells, which have regenerative potential, into damaged tissue to treat disease or injury. "After talking to Richard, I didn't have the money, but I knew I was going to go," Harrell said. "I mean, what did I have to lose? I knew where I was headed if I didn't go. I was going downhill fast. So why wouldn't I go try this?" Friends, family and fellow coaches held fundraisers for Harrell's treatments. Harrell's first trip to Panama, which was four weeks, cost $40,000. He has been back twice more, the last time in September.

It wasn't until the third visit that Harrell saw dramatic results. "MS is like a two-hump camel," Humphries said. "You can get over the first hump of active T-Cells fairly easily, but the second hump, the memory T-Cells, sometimes bring our MS symptoms back, as it did with Sam. "He was extremely disappointed for taking the two steps back after three steps forward. I told him it may take another two or three treatments to really get you going again. Needless to say, he could not stop smiling and was greatly relieved. Now, he is seeing the results." Harrell is a strong Christian and is quick to credit God and prayer for his recovery. But he also is a big believer in stem cell therapy.

Kathy Harrell is a more recent convert. She was skeptical until seeing the change in Harrell. "I just feel really grateful that these are good days and good months, and I'm not going to worry about next year," Kathy Harrell said. "It just makes you thankful that things are good right now, and he's pretty mobile. This disease reminds you to just be thankful for the day, so that's what we're doing. I realize now it can be worse." Charean Williams

Thursday, February 2, 2012

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

From National Institutes of Health, US National Library of Medicine

Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, Du MQ, Luan SL, Altmann DR, Thompson AJ, Compston A, Scott MA, Miller DH, Chandran S.

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

Abstract

BACKGROUND:
More than half of patients with multiple sclerosis have progressive disease characterised by accumulating disability. The absence of treatments for progressive multiple sclerosis represents a major unmet clinical need. On the basis of evidence that mesenchymal stem cells have a beneficial effect in acute and chronic animal models of multiple sclerosis, we aimed to assess the safety and efficacy of these cells as a potential neuroprotective treatment for secondary progressive multiple sclerosis.

METHODS:
Patients with secondary progressive multiple sclerosis involving the visual pathways (expanded disability status score 5·5-6·5) were recruited from the East Anglia and north London regions of the UK. Participants received intravenous infusion of autologous bone-marrow-derived mesenchymal stem cells in this open-label study. Our primary objective was to assess feasibility and safety; we compared adverse events from up to 20 months before treatment until up to 10 months after the infusion. As a secondary objective, we chose efficacy outcomes to assess the anterior visual pathway as a model of wider disease. Masked endpoint analyses was used for electrophysiological and selected imaging outcomes. We used piecewise linear mixed models to assess the change in gradients over time at the point of intervention. This trial is registered with ClinicalTrials.gov, number NCT00395200.

FINDINGS:
We isolated, expanded, characterised, and administered mesenchymal stem cells in ten patients. The mean dose was 1·6×10(6) cells per kg bodyweight (range 1·1-2·0). One patient developed a transient rash shortly after treatment; two patients had self-limiting bacterial infections 3-4 weeks after treatment. We did not identify any serious adverse events. We noted improvement after treatment in visual acuity (difference in monthly rates of change -0·02 logMAR units, 95% CI -0·03 to -0·01; p=0·003) and visual evoked response latency (-1·33 ms, -2·44 to -0·21; p=0·020), with an increase in optic nerve area (difference in monthly rates of change 0·13 mm(2), 0·04 to 0·22; p=0·006). We did not identify any significant effects on colour vision, visual fields, macular volume, retinal nerve fibre layer thickness, or optic nerve magnetisation transfer ratio.

INTERPRETATION:
Autologous mesenchymal stem cells were safely given to patients with secondary progressive multiple sclerosis in our study. The evidence of structural, functional, and physiological improvement after treatment in some visual endpoints is suggestive of neuroprotection.

FUNDING:
Medical Research Council, Multiple Sclerosis Society of Great Britain and Northern Ireland, Evelyn Trust, NHS National Institute for Health Research, Cambridge and UCLH Biomedical Research Centres, Wellcome Trust, Raymond and Beverly Sackler Foundation, and Sir David and Isobel Walker Trust.

Friday, January 27, 2012

Stem Cell Treatment for Multiple Sclerosis - "Everyone got their wish, plus more

  "...Everyone got their wish, plus more."
  Shelley Sims
 
 

Stem cell therapy patient, Shelley Sims, discusses her improvements following stem cell treatments at the Stem Cell Institute in Panama City, Panama. Shelley has reduced her medications from thirteen to two. She reports significantly decreased fatigue that has enabled her to start playing racquetball with her son as well as coach his basketball team - things she could never do before treatment.